1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genfit S.A.

Genfit S.A.

GNFTF
Genfit S.A.US flagOther OTC
9.50
USD
- -
- -
475.76MMarket Cap
Genfit S.A.
GNFTF
(Other OTC)

Recent

price

9.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.31
0.18
0.11
0.09
0.07
0.02
0.01
- -
- -
0.83
0.02
1.8
0.41
0.57
1.33
- -
Revenue per Share
-0.78
-0.75
-0.35
-0.63
-0.74
-0.69
-1.25
-1.79
-2.55
-1.76
-2.6
1.51
-0.48
-0.58
0.03
- -
Basic EPS, GAAP
-0.47
-0.56
-0.53
-0.47
-0.7
-0.63
-1.09
-1.69
-1.89
-1.34
-2.5
2.23
-1.47
-1.16
0.29
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.66
-0.49
-1.42
-0.38
-1.97
-2.54
-3.52
-4.83
-7.4
-7.94
-10.16
-7.3
-7.06
-7.59
-7.53
- -
Book Value per Share
0.69
0.34
0.44
0.7
3.06
2.22
5.29
3.23
0.65
2.25
-0.43
2.67
1.02
0.39
0.42
- -
Tangible Book Value per Share
12
13
15
20
23
25
27
31
31
37
39
45
49
50
50
- -
Basic Weighted Avg Shares
4
2
2
2
2
1
- -
- -
- -
31
1
80
20
29
67
65
Sales/Revenue/Turnover
-203.73
-328.26
-461.5
-548.51
-1,070.14
-3,353.13
-12,027.82
-48,039.83
-100,702.9
-187.58
-10,131.9
40.43
-135.26
-95.1
4.81
-81.86
Operating Margin (%)
1
1
1
- -
- -
1
1
1
2
3
4
3
2
2
2
2
Depreciation Expense
-9
-10
-5
-13
-17
-17
-34
-56
-80
-65
-101
67
-24
-29
2
-86
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.19
- -
- -
18.41
- -
Effective Tax Rate (%)
-249.65
-410.09
-323.6
-666.15
-1,054.83
-3,251.42
-11,854.58
-47,227.12
-115,247.83
-211.24
-13,231.5
84
-117.45
-101.15
2.25
-131.38
Profit Margin (%)
8
8
3
18
73
58
144
256
179
247
154
205
119
75
18
72
Working Capital
- -
10
8
6
5
4
5
162
166
179
181
72
70
62
6
108
LT Debt
8
4
7
14
70
55
143
101
21
84
-16
119
95
68
69
-23
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.96
- -
- -
1.92
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-31.27
- -
- -
-1.72
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.3%
-200.86%
-132.56%
Free Cash Flow
-56.55%
-164.85%
-303.58%
Net Income, GAAP
-594.77%
-1,237.94%
-5,804.58%
Sales/Revenue/Turnover
5,481.6%
2,093.09%
-2.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
3
14
- -
29
2024
- -
- -
- -
- -
67
2025
- -
- -
- -
- -
65

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.58
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
EQRx, Inc. (EQRXW)
Genmab A/S (GNMSF)
MYND Life Sciences Inc. (MYNDF)
GeneTether Therapeutics Inc. (GTTX.CN)
Atea Pharmaceuticals, Inc. (AVIR)
Sino Biopharmaceutical Limited (1177.HK)
Business
Genfit S.A., a biopharmaceutical firm, is dedicated to discovering and advancing therapeutic compounds and diagnostic innovations for significant metabolic and hepatic disorders. The company's lead compound, Iqirvo (elafibranor), has recently gained accelerated approval from the U.S. FDA in June 2024, followed by European Medicines Agency and MHRA approvals in September 2024, for the treatment of primary biliary cholangitis. Ipsen holds the global licensing rights for elafibranor, providing Genfit with milestone payments and royalties. Additionally, Genfit develops the NIS4 technology, a non-invasive blood test for identifying at-risk non-alcoholic steatohepatitis (NASH) and fibrosis, which powers Labcorp's commercially available NASHnext diagnostic. The pipeline also includes several programs focused on acute-on-chronic liver failure (ACLF), such as G1090N in Phase 1, and preclinical assets like SRT-015, CLM-022, and VS-02-HE, while development of VS-01 in ACLF was discontinued and is being re-prioritized for urea cycle disorder. Genfit also progresses GNS561, an investigational therapy for cholangiocarcinoma, through a collaboration with Genoscience Pharma. Established in 1999, Genfit S.A. is headquartered in Loos, France, and voluntarily delisted its American Depositary Shares from Nasdaq in November 2025.